Introduction: Population-wide screening for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements to inform cancer therapy in non-small-cell lung cancer (NSCLC) is recommended by guidelines. We estimated costeffectiveness of multiplexed predictive biomarker screening in metastatic NSCLC from a societal perspective in the United States.
T he expansion of targeted therapeutic options for metastatic non-small-cell lung cancer (NSCLC) is a welcome advance in a disease that historically has been resistant to treatment. Of the estimated 230,000 incident lung cancer cases annually, approximately 85% are diagnosed with NSCLC.
1,2 Most patients present with advanced disease, and adenocarcinoma is the most common histologic subtype. 2 Somatic mutations in epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements are found in 9.5% and 3.9% of unselected NSCLCs, respectively. 3 Patients whose tumors carry a sensitizing mutation of EGFR or ALK gene rearrangements experience higher response rates, longer progression-free survival (PFS), and improved quality of life when treated with a tyrosine kinase inhibitor (TKI) compared with platinum-based doublet chemotherapy. Guidelines recommend the ascertainment of EGFR and ALK mutational status to help guide first-line systemic therapy in all patients with nonsquamous, advanced NSCLC. 4 According to these recommendations, over 130,000 newly diagnosed NSCLC patients each year should undergo predictive biomarker screening. 5 But biomarker screening appears to be underutilized in routine care. Only 12% of acute care hospitals in the United States used the EGFR assay in 2010, which represented only 5.7% of guideline-directed patients. 4, 5 In addition, recent evidence questions the cost-effectiveness of biomarker screening. 6 Even among patients whose tumors are tested for predictive biomarkers, uncertainty surrounding the optimal timing of TKI therapy initiation adds to the complexity of treatment decision-making. 7 Turn-around-time (TAT), the time from tissue sample acquisition to reporting of test results, and inadequate tissue sample for analysis may tip the scale toward commencing empiric treatment with chemotherapy. Once test results reveal the presence of an actionable mutation after empiric therapy is begun, indirect evidence suggests that continuation of chemotherapy for four to six cycles before switching to a TKI may optimize outcomes. 7, 8 In the present analysis, we compared a number of TKI initiation strategies.
Multiplex detection of mutations has the advantage of tissue preservation and faster TAT. To date, economic analyses of screening for drug sensitivity biomarkers in lung cancer have restricted their focus on single biomarkers. 6, [9] [10] [11] [12] [13] [14] [15] [16] [17] We examined two molecular markers, EGFR mutations and ALK rearrangements, for which the evidence is sufficiently mature to support population-wide screening. 4 The goal of this article was to assess the cost-effectiveness of multiplexed predictive biomarker screening from a societal perspective in patients newly diagnosed with metastatic NSCLC living in the United States.
MATERIALS AND METHODS

Model and Treatment Strategies
We constructed a microsimulation, state-transition model to estimate the life expectancy and costs of four strategies: a "No Test" approach, treatment with cisplatin-pemetrexed (CisPem) chemotherapy and no biomarker testing, and two different empiric treatment strategies in which CisPem was initiated with concurrent biomarker testing. In one, the "Empiric therapy" strategy, chemotherapy was continued for four cycles followed by TKI maintenance treatment in mutation-positive patients. In the other, the "Empiric switch therapy," patients initiated firstline chemotherapy, and those with mutation-positive tumors switched to a TKI immediately upon return of test results; and finally, the "Test-treat" strategy, in which molecularly guided treatment was initiated only after results of testing became available. The simulated study population composed of newly diagnosed stage IV NSCLC patients with nonsquamous histology. Figure 1 depicts the structure of the model. For all testing strategies, patients entered the model in the prescreen state on the day the test was ordered. If the sample was suitable for testing, the patient transitioned to the test sequence health states. With a daily cycle length, we were able to model wait times for test results before initiation of therapy. Patients with insufficient tumor samples from initial diagnostic samples transitioned to the rebiopsy prescreen state to account for elapsed time in determining appropriateness for a rebiopsy and for performing the procedure. Patients who did not undergo a rebiopsy, or whose rebiopsy samples were inadequate for testing, transitioned to the treatment states. Multiplexed molecular testing proceeded according to a two-step test sequence: concurrent EGFR mutation and ALK overexpression assays followed by ALK fluorescence in situ hybridization (FISH) confirmation for ALK immunohistochemistry (IHC)-positive results (1+, 2+, or 3+). 4 Mortality risk in the above health states was modeled based on the natural history of advanced NSCLC for the "Test-treat" approach and the first-line CisPem therapy for the empiric treatment strategies.
Patients in the "No test" strategy entered the model in the first-line CisPem treatment state (Fig. 1) . Upon progression on each therapy, patients transitioned to the next line of therapy based on treatment conditional disease risk of progression. Treatment sequences for the other strategies ( Table 1 ) followed the same model structure.
For the main analysis, we chose a time horizon of 2 years to capture the major health and economic consequences in metastatic NSCLC. This duration obviated the need for projecting survival outcomes beyond the primary clinical trial data. 18 Benefits and costs were discounted at 3% per annum. Analyses were performed in TreeAge Pro 2013 (TreeAge Software, Inc., Williamstown, MA).
Natural History
We used data from Surveillance, Epidemiology, and End Results-Medicare to model the natural history of untreated, , who were managed with best supportive care were generated. The model was weighted using the inverse conditional probability of exposure to chemotherapy to balance observable covariates between treatment naive and chemotherapytreated patients. Time dependent transitional probabilities for the simulation model were calibrated to the predicted survival probabilities from the Cox proportional hazard model using a piecewise-exponential approach.
Clinical Outcomes
Randomized clinical trials (RCTs) for initiation and maintenance therapy with erlotinib and crizotinib in EGFR mutation and ALK rearrangement-positive patients, respectively, were identified for calculating treatment-conditional progression and survival estimates. Efficacy data for other therapies were pulled from RCTs that enrolled molecularly unselected patients. The trial-based median estimates for treatment-specific overall survival and PFS were used as calibration targets. Transition probabilities were calculated using a constant hazard assumption.
Quality of Life
We estimated utilities based on a mixed model, which included parameters for best tumor response and toxicities usually encountered with chemotherapy treatments in NSCLC (neutropenia, febrile neutropenia, fatigue, diarrhea, nausea and vomiting, rash, and hair loss). 19 We used rates for best tumor response and grades 3 and 4 adverse drug events (ADEs) from RCTs to calculate treatment-specific utilities based on the mixed model ( Table 2) . 19 Disutilities for ADEs were incorporated in the first month of therapy.
11,20
Genomic Markers
Prevalence rates of biomarkers were drawn from a population-based registry (Table 2 ) of 10,000 NSCLC patients who were enrolled for routine screening of predictive biomarkers.
We estimated that 30% of patients would undergo a rebiopsy, and 85% of repeat biopsies would yield adequate samples for molecular testing. 10 The distribution of repeat biopsy techniques (bronchoscopic, or transthoracic needle aspiration of primary cancer, and metastatic site needle aspirations) and pneumothorax complication rates were based on a prior analysis. 10 We used ALK FISH positivity as the reference standard for presence of ALK rearrangements. 4, 25 Estimates for IHC test performance were taken from the largest published case series evaluating a novel 5A4 monoclonal antibody (Table 1) .
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Costs
Cancer-related medical costs, costs of travel, and patient time spent seeking medical care were included in the model (Table 2) . We used the Centers for Medicare and Medicaid Services reimbursement rates for each biomarker assay in our base-case analysis and for other direct medical costs, including drug administration, imaging, and ADEs. Costs for treatment specific ADEs were assumed to accrue in the first month of therapy. 11, 20 The average sale price and average wholesale price were used to value injectable and orally administered drugs, respectively. With the exception of CisPem chemotherapy, which was administered up to four cycles, patients were assumed to accrue drug-related costs up to the time of progression. Costs for rebiopsy and related complications were derived from the analysis by Handorf et al. 10 The cost for treating progressive disease was based on lung cancer attributable costs in the last year of life. 34 All costs in the model were adjusted to 2013 values using the gross domestic product deflator series. 
Cost-Effectiveness Analysis
We calculated the incremental cost-effectiveness by ranking the strategies in order of increasing effectiveness. Strongly dominated strategies, those that had a lower or equal effectiveness and higher costs, were eliminated. Incremental cost-effectiveness ratios (ICERs) were calculated for each strategy in relation to the next best strategy. The ICER is a ratio of the difference in mean costs divided by the difference in mean quality-adjusted life years (QALYs). Strategies with a higher ICER that were less effective than another strategy were eliminated by extended dominance. The ICERs were recalculated for the remaining nondominated strategies. 38 
Sensitivity Analyses
We conducted sensitivity analyses to evaluate which parameters were most influential on model results. Where available, the ranges used for the parameters corresponded to the 95% confidence intervals (Table 2 ). Costs were varied ±20%, and plausible ranges for TATs were used based on expert opinion. We also simulated the lifetime (5 year) costs and effectiveness where prognosis beyond trial observation period was modeled using exponential distributions. In addition, model outputs were generated based on commercial prices for molecular assays and proportion of patients tested. We also ran a sensitivity analysis for the transition probability of dying while awaiting test results based on treatment naive patients who were randomized to best supportive care in a RCT. 39 Finally, we conducted a threshold sensitivity analysis by varying the TAT for testing and results to determine the break-even point at which the expected benefits of the "Empiric therapy" approach would be equivalent to the "Test-treat" strategy.
RESULTS
Multiplexed testing approaches of "Test-treat" and "Empiric switch" were most effective (Table 3) . Both yielded an average life expectancy of 0.97 life years (LYs) and 0.56 QALYs, which represents 0.04 and 0.03 increases in LYs and QALYs, respectively, compared with no test and treatment with standard chemotherapy. The "Empiric therapy" approach, in which chemotherapy was continued for four cycles before initiation of molecularly guided therapy, was less effective (0.95 LYs and 0.55 QALYs). Because the "Empiric switch" approach was more expensive than the "Test-treat" strategy (but equally effective), it was ruled out by strong dominance. The "Empiric therapy" approach was eliminated by extended dominance because it was associated with a higher ICER than the "Test-treat" approach. Compared with the "No test" strategy, the "Test-treat" approach of concurrent EGFR mutation and ALK IHC testing followed by ALK FISH confirmation before initiation of any therapy yielded an ICER of $136,000 per additional QALY (0.03 additional QALYs and $4082 extra spending). Without adjustment for quality of life, the "Testtreat" approach had an ICER of $102,000 per LY gained compared with the "No test" strategy.
Sensitivity Analyses
Changing the parameters values over ranges listed in Table 2 did not impact the rank order of the strategies. Also, both empiric treatment strategies remained dominated. A comparison of the nondominated strategies revealed that the most influential parameters were utilities and acquisition costs for TKIs (Fig. 2) . We found that the ICER for the "Test-treat" approach compared with the "No test" strategy ranged from $124,000 to $157,000 per additional QALY, with high and low utility values, respectively; and from $83,000 to $190,000 per QALY gained when costs of TKI therapy were varied by minus and plus 20%, respectively. In all other scenarios, the ICER for "Test-treat" compared with "No test" ranged from $130,000 to $150,000 per QALY.
Commercial prices for assays had a small effect on the ICER ($148,000 per QALY for the "Test-treat" vs. "No test" strategy). Extrapolation of long-term survival increased the ICER for "Test-treat" to $148,000 per QALY compared with "No Test." With a trial-based mortality risk in the pretreatment health states (using a piecewise exponential model with survival probabilities of 97% and 90% at 1 and 2 months after diagnosis, respectively), the same dominance pattern was observed and the ICER remained stable for the "Test-treat" strategy compared with "No Test" ($153,000/QALY). 39 Varying the proportion of patients for whom multiplexed molecular testing is ordered showed that decreasing this proportion to 5.7%, from 100% in the base-case analysis, would lower the outcomes in terms of expected QALYs to 0.54 for all testing strategies. 5 Finally, our threshold analysis of TATs revealed that increasing the wait times for testing and results by 1.5-fold of the base-case estimates would render the "Empiric therapy" approach equivalent in terms of expected benefits to the "Test-treat" strategy, at 0.55 QALYs each.
DISCUSSION
Concurrent EGFR mutation and ALK IHC testing with ALK FISH confirmation for tumors that overexpress the ALK protein before initiation of therapy yielded an ICER of $136,000 per QALY gained compared with no testing and treatment with chemotherapy alone. Whether or not an ICER of $136,000 provides good value is contingent upon the willingness-to-pay threshold, which serves as a guide of how much society is willing to pay for an additional QALY. The World Health Organization (WHO) defines interventions with ICERs within three times the gross domestic product per capita as being cost-effective (approximately $155,000 in the United States in 2014). 40 Others posit that a threshold of $200,000 per QALY may be more appropriate based on empirical data of ICERs for often used interventions. 41, 42 Using these benchmarks, our results suggest that multiplexed testing followed by molecularly guided therapy in metastatic NSCLC provides good value from a societal perspective.
Our simulation study confirms that waiting for test results before initiation of treatment optimizes outcomes in newly diagnosed patients with metastatic NSCLC. 7 Although empiric therapy in which chemotherapy is initiated concurrently with testing for mutations, followed by an immediate switch to molecularly guided therapy at the time test results become available yielded the same life expectancy as the test then treat approach, the former strategy was dominated Costs and life expectancy outcomes were discounted at a 3% annual rate. The "Empiric therapy" approach composed of CisPem continuation for four cycles before start of molecularly guided therapy. In the "Test-treat" approach, molecularly guided therapy was initiated after ascertainment of test results. In the "Empiric switch therapy," concurrent initiation of CisPem and testing was modeled followed by an immediate switch to test-result conditional treatment after one cycle of CisPem.
b Compared with the next-best strategy in terms of effectiveness. because it was more expensive. Continuation of empiric chemotherapy for four cycles before switching to test-result conditional treatment yielded less favorable outcomes than the above two approaches, both in terms of QALYs and LYs. This strategy was eliminated by extended dominance. These results were robust to variations over plausible ranges of model parameters.
In sensitivity analyses, the ICER was highly sensitive to drug acquisition costs. At lower TKI prices (80% of brand name product price), the ICER for the "Test-treat" strategy decreased to $83,000 per QALY compared with standard treatment with chemotherapy. Over time, once generic versions of TKIs become available, these innovations will confer even better value. The optimal price point that maximizes social welfare, while minimizing the impact on technological innovation, is outside the scope of this analysis. However, growing concerns over the increasing cost burden of these innovations on patients deserve scrutiny. [43] [44] [45] Patient access to these drugs may be impeded by onerous out of pocket costs. One way to attenuate the impact of cost sharing may be through valuebased benefit design. Arguably, breakthrough therapies that offer substantial improvement in outcomes and are placed into lower cost sharing tiers would benefit society as a whole from healthier patients who remain productive, as they are able to access these beneficial treatments.
We were unable to identify published economic analyses that examined multiplexed testing in advanced NSCLC. Handorf et al. evaluated the cost-effectiveness of molecularly guided first-line therapy using EGFR mutation testing in the United States from a payer perspective. The ICERs for testing with and without rebiopsy and EGFR mutation guided treatment ranged from $110,644 to $122,219 per QALY gained compared with treatment with a carboplatin-paclitaxel doublet. 10 Similar to our analysis, the cost-effectiveness results from that study support the value of molecularly guided therapy. Another recently published study examined the costeffectiveness of ALK rearrangement testing alone before first-line crizotinib treatment in ALK-positive tumors or cisplatin-gemcitabine combination chemotherapy in wildtype tumors. 6 From a Canadian public health perspective, that analysis generated an ICER of $255,970 per additional QALY for molecularly guided therapy compared with chemotherapy. The authors concluded that genetic testing and treatment with molecularly guided therapy was not cost-effective. Unlike the Canadian study, we combined multiplexed testing in our analysis of the two molecular markers that are guideline-recommended for population-wide screening in advanced NSCLC, which de facto produced better outcomes for the molecular testing strategy because more patients benefit from testing.
Our results are subject to modeling assumptions and need to be interpreted in this context. For example, due to treatment crossover after progression and lack of direct comparisons in RCTs, we relied on single-arm data for our parameters. Furthermore, we used data from PROFILE 1007, a phase 3 RCT of second-line crizotinib, to inform hazard rates in our model for overall survival and PFS. 25 These estimates apply to a small subset of patients in our model, those with ALK rearrangement-positive status. Any bias introduced into the model would thus be marginal given the size of this subgroup. 46 Overall, varying the hazard rates for treatment effects in sensitivity analyses revealed that the base-case results were robust to these assumptions. Also, we used Medicare reimbursements as a proxy for the societal costs of test assays. However, the true costs of the tests may vary across providers. But even with commercial test prices, the ICER for the "Test-treat" compared with the "No test" strategy increased to $148,000 per additional QALY, which is still below commonly acceptable willingness-to-pay thresholds. 41 In summary, our analysis suggests that multiplexed testing for EGFR mutations and ALK overexpression with an IHC assay followed by ALK rearrangement confirmation with FISH for IHC-positive results and biomarker conditional treatment is a cost-effective strategy compared with treatment with chemotherapy and no testing in metastatic NSCLC. Empiric
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